Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Background Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy. We aimed to evaluate the safety profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate compos...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Annunziata, Christina M., Kohn, Elise C., LoRusso, Patricia, Houston, Nicole D., Coleman, Robert L., Buzoianu, Manuela, Robbie, Gabriel, Lechleider, Robert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2012
Gaiak:
Phase I Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553417/
https://ncbi.nlm.nih.gov/pubmed/22370972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9801-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak